KIMBERLY MARSHALL: Open Payments
NPI 1386971075 · OWENSBORO, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$354 in 16 payments from 8 companies in 2025. Trend: 2023 $1,580 · 2024 $1,784 · 2025 $354
Food & beverage: $354
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 4 | $104 |
| Janssen Biotech, Inc. | 3 | $64 |
| Madrigal Pharmaceuticals | 2 | $49 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $43 |
| Lilly USA, LLC | 2 | $37 |
| Gilead Sciences, Inc. | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Ardelyx, Inc. | 1 | $15 |
Products named: RINVOQ, TREMFYA, REZDIFFRA, XIFAXAN, OMVOH, ENTYVIO, SKYRIZI, IBSRELA.
Industry payments across KY — which companies pay providers there.
